AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 154 min read$ENSC

Ensysce Biosciences, Inc. (ENSC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001716947 0001716947 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jul 15, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$ENSC
Neutral
medium confidence
Mentioned
$ENSC
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ENSCNeutralLow
01

Why it matters

Management turnover can change execution risk and investor confidence, but without new financial data or guidance, the impact is likely incremental unless succession details are unfavorable.

02

Market read

This is a governance and leadership update that may affect short-term sentiment, but the excerpt lacks hard financial or operational catalysts.

03

What to watch

Traders should look for the full 8-K exhibits and any named successor or board changes, since the excerpt provided does not include those specifics.

Relevance 6/10Novelty 5/10Timing: filed July 15, 2026 after July 10 COO resignation

Background

The company filed an SEC Form 8-K under Item 5.02 for officer departure and related director/officer election and compensatory arrangements.

Company-level read

Ticker impact

$ENSCNeutralMedium confidence
Context

Ensysce Biosciences disclosed via 8-K that COO Jeffrey Millard resigned effective July 10, 2026, triggering officer/board changes.

Expected impact

Likely limited, with any reaction driven by market interpretation of succession and continuity rather than new fundamentals.

Evidence & confidence

This is an SEC 8-K Item 5.02 covering resignation and related appointments/comp arrangements, but the provided text includes no details on replacement, rationale, or financial impact.

Market effects

Sector

Minimal sector read-through; this is company-specific governance/management news.

Regional

No clear regional spillover indicated.

Global

No global market linkage indicated.

Counterpoint

What could challenge this read

The resignation may be routine or planned, and the 8-K’s mention of election/appointment and compensatory arrangements suggests the company has a prepared succession plan.

Key entities

  • issuer
    Ensysce Biosciences, Inc.

    Nasdaq-listed company filing Item 5.02 8-K regarding officer departure and related appointments/comp arrangements.

  • officer
    Jeffrey Millard

    Chief Operating Officer who resigned effective July 10, 2026.

  • executive
    Lynn Kirkpatrick

    President and Chief Executive Officer who signed the filing.

Read at source← All news

Related articles

AUG 7
$ENSCMedAI 8/10

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing

Ensysce Biosciences (NASDAQ:ENSC) completed its acquisition of Cy Biopharma, adding clinical-stage pain drug CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation. Ensysce secured up to $77 million via cash contribution, private placement, and milestone funding. Cy Biopharma shareholders are expected to own about 74.94% after preferred conversion.

yahoo.com5 min
AUG 6
$ENSCMed

Ensysce Biosciences, Inc. (ENSC): Completion of Acquisition or Disposition of Assets

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: ensysce biosciences, Inc., a Delaware corporation; PHRMA MERGER SUB I, INC., a Delaware corporation; PHRMA MERGER SUB II, LLC, a Delaware limited liability company; and Cy Biopharma, Inc., a Delaware

SEC EDGAR 8-K6 min
MAY 28
$ENSCMedAI 9/10

Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences (NASDAQ:ENSC) reported a sharp rise in short interest: 814,605 shares as of May 15, up from 52,730 on April 30, with about 5.7% of shares sold short and a days-to-cover ratio of 0.1 (based on average daily volume). The stock traded at $0.30. The company reported May 15 quarterly EPS of -$0.52 and revenue of $0.96M.

dailypolitical.com2 min
AUG 8
$BPMedAI 8/10

BP Chair Who Sped Up Company’s Turnaround Fired Over Conduct

BP PLC fired Chairman Albert Manifold months after he took the role, citing serious concerns about governance standards, oversight, and conduct, according to BP’s board. BP shares fell about 9.3% after the news, with the stock at 529 pence in London. The move adds to leadership churn as BP seeks a turnaround under CEO Meg O’Neill.

energynow.com4 min
AUG 8
$000660.KSMed

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.

businesstimes.com.sg3 min